David Southwell

One of the things that we've recently discovered is a biomarker that predicts patients that are gonna be, that are gonna respond to our drug.

And the biomarker exists in well over 50% of the patients.

So we can take, we can do a pan-cancer study and we actually used sub-therapeutic doses for some of these,

You do a pan-cancer study that has an ORR rate that is not that good of, say, 14%.

You then apply the biomarker to it and you get that up to 37.5%, which is much more interesting.

So we are developing, you know, we started with a monotherapy.

We then have found a biomarker for it and we're working very hard with that.

with the objective of doing a pan-cancer pivotal trial with it.

The other great thing about chromosomal instability is many of the standards of care promote, they create chromosomal instability.

So, for example, taxanes, which are part of the first-line therapy of many cancers, including lung cancers, only have about a 10% to 15% response rate.

In other words, the

The tumor goes down by more than 30% in only 10 or 15% of cases.

What we've found preclinically is that if you take a cell line that doesn't work with our drugs, so it's not particularly chromosomally unstable, you give our drug, nothing happens at all.

You give a taxane, it has a little bit of an effect.

But if you give both of them, you have a synergistic effect and it effectively flatlines the tumor.

So we really have two approaches.

One is a biomarker directed monotherapy approach, which would be used in third line therapy in a lot of different cancers.

And our plan is to do a pan cancer study of that.

And secondly, a combination strategy.

where you would combine it with taxanes or ADCs.